Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 11/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918305 | 0.99 | CHRM4 (0.45) | CHRM4FFAR4HRH1CCR3KCNH2 | |
| SCHEMBL2917310 | 0.98 | CHRM4 (0.45) | CHRM4FFAR4HRH1CCR3KCNH2 | |
| SCHEMBL2916320 | 0.96 | CHRM4 (0.46) | CHRM4FFAR4HRH1CCR3KCNH2 | |
| SCHEMBL2916220 | 0.93 | CHRM4 (0.46) | CHRM4FFAR4HRH1CCR3KCNH2 | |
| SCHEMBL2918388 | 0.92 | FFAR4 (0.47) | CHRM4FFAR4HRH1CCR3KCNH2 | |
| SCHEMBL2914958 | 0.89 | ITGB3 (0.41) | CHRM4HRH1CCR3KCNH2CHRM2 | |
| SCHEMBL13212985 | 0.88 | ITGB3 (0.42) | FFAR4HRH1CCR3KCNH2ITGB3 | |
| SCHEMBL4124559 | 0.88 | CHRM4 (0.39) | CHRM4FFAR4HRH1CCR3KCNH2 | |
| SCHEMBL2909717 | 0.88 | ITGB3 (0.41) | CHRM4HRH1CCR3KCNH2CHRM2 | |
| SCHEMBL2917223 | 0.87 | CHRM4 (0.43) | CHRM4FFAR4GCGRCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | claimed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | CHRM4 2743/4885FFAR4 207/4885HRH1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.